Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Pipeline Monitor
Market beckons for another melanoma drug
BMS' Opdivo in melanoma, new anticoagulant Lixiana, an antidote for Pradaxa and Amgen's PCSK9 inhibitor all made important steps towards market during the week as did Biogen and AbbVie's MS drug Zinbryta.
Special Report
Positives outnumber negatives from March PBAC
Positive recommendations outnumbered rejections from the March PBAC meeting with 19 major submissions given the go-ahead, 12 knocked back and three deferred. Full results inside.
PBS Top Five
Dermatology - Psoriasis drugs dominate
In this new regular feature, we analyse the PBS market by market with the focus on F1 drugs. Inside you'll find the top five dermatology brands, the top five companies in dermatology and the fastest growing brands and companies by both value and volume with growth rates and PBS on-patent dermatology market shares.